OBJECTIVES: Pentraxin 3 (PTX3) may reflect local inflammatory status in tissues and thus serve as a potential biomarker of inflammation. Here, we investigated the utility of serum PTX3 as an index for assessing the 90-day prognosis of acute minor stroke patients. MATERIALS & METHODS: Acute minor stroke patients (N = 241) and matched healthy control subjects (N = 241) were prospectively recruited. Clinical, laboratory, and imaging data were assessed. Blood samples were collected within 48h after acute minor stroke onset and serum PTX3 levels were determined. RESULTS: Significant increases in stroke patients versus controls were obtained for serum PTX3 (3.14 ± 1.23 vs. 2.44 ± 0.74 ng/ml; p < .001) and C-reactive protein (CRP - 1.53 ± 0.38 vs. 1.35 ± 0.35 μg/ml; p < .05). Among the four stroke subtypes, as defined by modified Trial of Org 10172 in Acute Stroke Treatment classification, there were no statistically significant differences in serum PTX3 levels (p > .05). Multivariate logistic regression analysis revealed that serum PTX3 and LDL cholesterol could predict unfavorable outcomes at day 90 in Large Artery Atherosclerosis (LAA) patients. CONCLUSIONS: Serum Pentraxin 3 may serve as an independent predictor for an unfavorable outcome in the LAA subtype of acute minor stroke and may possess a superior prognostic value as compared to CRP in this LAA subgroup.
OBJECTIVES: Pentraxin 3 (PTX3) may reflect local inflammatory status in tissues and thus serve as a potential biomarker of inflammation. Here, we investigated the utility of serum PTX3 as an index for assessing the 90-day prognosis of acute minor stroke patients. MATERIALS & METHODS: Acute minor stroke patients (N = 241) and matched healthy control subjects (N = 241) were prospectively recruited. Clinical, laboratory, and imaging data were assessed. Blood samples were collected within 48h after acute minor stroke onset and serum PTX3 levels were determined. RESULTS: Significant increases in stroke patients versus controls were obtained for serum PTX3 (3.14 ± 1.23 vs. 2.44 ± 0.74 ng/ml; p < .001) and C-reactive protein (CRP - 1.53 ± 0.38 vs. 1.35 ± 0.35 μg/ml; p < .05). Among the four stroke subtypes, as defined by modified Trial of Org 10172 in Acute Stroke Treatment classification, there were no statistically significant differences in serum PTX3 levels (p > .05). Multivariate logistic regression analysis revealed that serum PTX3 and LDL cholesterol could predict unfavorable outcomes at day 90 in Large Artery Atherosclerosis (LAA) patients. CONCLUSIONS: Serum Pentraxin 3 may serve as an independent predictor for an unfavorable outcome in the LAA subtype of acute minor stroke and may possess a superior prognostic value as compared to CRP in this LAA subgroup.
Authors: Urs Fischer; Adrian Baumgartner; Marcel Arnold; Krassen Nedeltchev; Jan Gralla; Gian Marco De Marchis; Liliane Kappeler; Marie-Luise Mono; Caspar Brekenfeld; Gerhard Schroth; Heinrich P Mattle Journal: Stroke Date: 2010-02-25 Impact factor: 7.914
Authors: Ivana Rajkovic; Raymond Wong; Eloise Lemarchand; Jack Rivers-Auty; Olivera Rajkovic; Cecilia Garlanda; Stuart M Allan; Emmanuel Pinteaux Journal: J Mol Med (Berl) Date: 2018-10-13 Impact factor: 4.599
Authors: Giuseppe A Ramirez; Patrizia Rovere-Querini; Miriam Blasi; Silvia Sartorelli; Maria Chiara Di Chio; Mattia Baldini; Rebecca De Lorenzo; Enrica P Bozzolo; Roberto Leone; Alberto Mantovani; Angelo A Manfredi; Enrico Tombetti Journal: Front Immunol Date: 2019-05-29 Impact factor: 7.561
Authors: Siarhei A Dabravolski; Vasily N Sukhorukov; Vladislav A Kalmykov; Nikolay A Orekhov; Andrey V Grechko; Alexander N Orekhov Journal: Int J Mol Sci Date: 2022-01-07 Impact factor: 5.923